Abstract
Revisions of drug package inserts (PIs) may be made immediately after approval or after considerable clinical experience; however, it is unclear whether there is a relationship between the characteristics of these safety measures and the period since drug approval. Here, we analyzed 209 cases of safety measures (revisions of the PIs) taken in Japan over 5 years (FY2014 to FY2018). The median, minimum, and maximum period from approval date in Japan to PI revision date was 6.29 years (interquartile range 2.68-15.53 years), 0.16 years, and 59.69 years, respectively. The cases were classified into four groups depending on types of adverse reaction and therapeutic category in relation to the national approval date and international birth date, resulting in the grouping together of particular adverse reactions and therapeutic drugs. For example, "Hepatobiliary disorders", "Blood and lymphatic system disorders", "Respiratory, thoracic and mediastinal disorders", "Antineoplastics", "Chemotherapeutics", and "Other agents affecting metabolism" were associated with the group of safety measures taken early after approval of a drug soon after the international birth date, suggesting that careful attention at an earlier stage after approval ...Continue Reading
References
Dec 14, 1995·The New England Journal of Medicine·J C RoujeauF Locati
Jul 1, 1996·Journal of Clinical Epidemiology·B RzanyE Schöpf
Dec 23, 1998·Japanese Journal of Clinical Oncology·Y Fujiwara
Feb 13, 2001·Journal of Cutaneous Pathology·A SidoroffJ C Roujeau
Jul 16, 2010·Journal of Clinical Pharmacology·Kae NakashimaMasahiro Takeuchi
Jan 3, 2013·Pharmacoepidemiology and Drug Safety·Jean LesterGerald Dal Pan
Nov 12, 2013·Clinical Pharmacology and Therapeutics·T UenoY Uyama
Nov 28, 2013·Clinical Pharmacology and Therapeutics·F L ArnoldS Ono
Apr 17, 2014·Pharmacoepidemiology and Drug Safety·Norio TamuraTsutomu Matsuda
Dec 17, 2014·Modern Rheumatology·Ken-Ei SadaUNKNOWN Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan
Apr 1, 2014·Clinical Journal of Gastroenterology·Kazuhiko MoriHiromu Kutsumi
May 26, 2016·Pharmacoepidemiology and Drug Safety·Chieko IshiguroTomiko Tawaragi
Nov 15, 2016·Gut and Liver·Nobuyuki Toshikuni
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Jul 20, 2017·Pharmacoepidemiology and Drug Safety·Chieko IshiguroTadashi Izawa
Oct 24, 2017·Pharmaceutical Medicine·Makoto Fujikawa, Shunsuke Ono
Nov 16, 2017·Clinical and Translational Science·Kunihito AsanoMasahiro Tohkin
Dec 22, 2017·Clinical Pharmacology and Therapeutics·Ellen PinnowGerald Dal Pan
Apr 5, 2019·Pharmacoepidemiology and Drug Safety·Kaori YamadaUNKNOWN MID-NET® project group
Nov 7, 2019·Therapeutic Innovation & Regulatory Science·Shray Bablani, Manthan D Janodia